5.2 years; p=0.001) but longer survival (12.5 years vs. 9.5 years; p<0.0001) compared to patients >55 yrs. However, patients ≤ 55 had significantly shorter survival than age-and sex-matched normal population (12.5 years vs. not reached; p<0.0001). Our study is the first comprehensive analysis of younger chronic lymphocytic leukemia patients in the modern era. Adverse prognostic markers appear more common among young patients. Although the survival of young chronic lymphocytic leukemia patients is longer than those >55, their 4 survival relative to the age-and sex-matched normal population is profoundly shortened.
and have compared those to older CLL patients. These historical series were small (e.g. <200 patients) and are more than two decades old. (6, (8) (9) (10) (11) The most recent and largest series was reported in 1999 and included 204 patients. Due to these profound changes, data from historical reports on clinical outcomes of younger patients with CLL are of uncertain relevance in the modern era. (6, (8) (9) (10) (11) In the present study, we aim to describe the clinical characteristics, time to first treatment (TFT) and overall survival (OS) of CLL patients ≤ 55 years in the current era.
METHODS

Patients
The Mayo Clinic CLL database includes all patients with a diagnosis of CLL seen in the Division of Hematology at Mayo Clinic since 1995, and who permit their records to be used for research purposes. (Table 1) , the absolute differences were small and thus unlikely to be of clinical significance. As would be expected in an older population, a significantly higher proportion of patients in the >55 year age group had an ECOG performance status of >0.
RESULTS
Baseline Characteristics of
We next divided patients (Table 3 , supplementary appendix).
Time to First Treatment and Overall Survival
Comparison of OS with the general population
As a group, CLL patients ≤ 55 have significantly shorter OS than the ageand sex-matched population (median CLL=12.5 yrs; median population=not reached; p<0.0001, Figure 3A ). However, patients ≤ 55 who were Rai Stage 0 and IGHV mutated had comparable survival to the age-and sex-matched general population (p=0.97, Figure 3B ). Similarly, patients ≤ 55 who were Rai Stage 0 and had either 13q-or normal FISH also had a comparable survival to the age-and sex-matched general population (p=0.27, Figure 3C ).
Among the 358 young patients with both FISH and IGHV results available, 171 were Rai stage 0. Of these 171 patients, 97 (56.7%) had both mutated IGHV and a favorable FISH risk category, 54 (31.5%) had 1 unfavorable factor and 20 (11.7%) had 2 unfavorable factors. The median survival in the 0, 1, and 2 unfavorable groups are not reached, 13.0, and 7.7 years, respectively (p<0.001, Figure 3D ).
DISCUSSION
Considerable advances have been made in our ability to predict outcome and treat patients with CLL in the past decade. This study is the first comprehensive report on the clinical characteristics and outcomes of a cohort of young CLL patients (≤55 years) in the modern era and is approximately four times larger than any previous series of young CLL patients. Slightly more than half (55%) of the patients also had information on IGHV gene mutation status and genetic abnormalities detected by FISH providing insight into the associations between age and molecular biomarkers. Significant differences in the presentation of young CLL patients relative to older patients were observed: young patients were more likely to present with intermediate Rai risk disease, have unmutated IGHV gene mutation status and express ZAP-70. Although the OS of young CLL patients as a group is longer than CLL patients >55 years, their survival is profoundly shorter than age-and sex-matched population.
To the best of our knowledge, our study is the first to report that young CLL patients are enriched with adverse clinical and biological characteristics. These differences persist when we limit our analysis to non-referred patients and became even more pronounced when patients ≤ age 55 underwent further age sub-stratification. This observation suggests that young CLL patients are more likely to have a biologically aggressive disease compared to older patients. CLL patients ≤ age 55 were treated sooner (median TFT: 4 years) than those >55 (median TFT: 5.2 years).It is possible that healthcare providers may have a bias in treating young CLL patients sooner than older CLL patients who may have multiple other co-morbidities. However, the fact that the shorter TFT among young patients was no longer significant after adjusting for Rai stage and IGHV mutation status suggests that the shorter TFT among young patients is driven by differences in disease biology rather than age or the impact of co-morbidities.
There were no differences noted in TFT amongst the subgroups (9) could not identify any distinctive clinical or prognostic features (e.g., stage, ALC, bone marrow histology) among young patients relative to older patients. The median OS of their cohort was 12 years. In 1994, Molica et al (8) published their experience of 53 young CLL patients. There were no significant differences in traditional prognostic factors in these patients compared to older adults; the median OS was 7.1 years compared to 4.1 in the older age group. Two subsequent retrospective series (each with ~200 patients ≤ age 55) confirmed these results. (7, 30) Although the vast majority of the aforementioned studies did not report any differences in the traditional prognostic parameters between young and old CLL patients, we did find significant differences in these two populations of patients in the modern era. It is notable that cohorts of patients with CLL cared for in the 1970's and 1990's all have the same median OS of 12 years. This is exactly what we find in our study more than 3 decades later, which is a reminder that we need to be vigilant in evaluating and offering treatment options that improve not only disease-free survival but OS as well.
Our study has several limitations. Not all patients had novel molecular/biologic parameters available for inclusion in multiple analyses, given that these have been used routinely in the past 5-10 years. Also, the treatment options for patients with CLL have undergone considerable changes during the study period. In addition, this was a single-center retrospective analysis which needs validation amongst other cohorts of patients. Although we find that young CLL patients with Rai 0 with favorable IGHV and FISH results have comparable survival to the general population over a 10 year interval, long term follow-up will be necessary to determine if this holds true.
In summary, this article helps formulate general concepts regarding the management and natural history of patients who experience the diagnosis of CLL well under the median age of this disease. Young CLL patients have an adverse clinical and molecular risk profile (i.e, Rai stage, IGHV mutation status) compared to older patients. As a collective group, the median OS of CLL patients ≤ age 55 is 12 years -which is significantly shorter than age-and sex-matched population.
Despite this discouraging group average, we found that approximately 25% young patients in our study who have Rai Stage 0 disease and either mutated IGHV genes or favorable FISH risk category (such as normal or 13q-) have a comparable survival to the age-and sex matched general population. Accordingly, information from prognostic testing of molecular biomarkers can be used to stratify outcome in younger patients and identify those most likely to benefit from participation of trials testing early intervention strategies. 
Statistical Analysis
Patients receiving early treatment (i.e., not meeting the 1996 CLL working group consensus criteria for treatment) as part of experimental protocols were censored as untreated on the date experimental therapy was initiated. The Kaplan-Meier method was used to estimate the probability of TFT and OS; Cox proportional hazards models were used to evaluate associations between TFT or OS and patient prognostic factors.
Since not all patients had all novel prognostic markers available, the independent value of each prognostic factor (e.g. CD38, CD49d, ZAP-70, IGHV mutation status, and FISH risk category) was assessed individually in separate models after adjusting for age, sex and Rai stage. Hazard ratios and 95% confidence interval were calculated from the Cox models. 
